A new liquid biopsy approach developed by Johns Hopkins Kimmel Cancer Center investigators could revolutionize brain cancer ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

A new study reveals that the way DNA folds inside brain cells plays a critical role in glioblastoma, one of the deadliest forms of brain cancer.

Researchers have made a major breakthrough that could transform IV medications into oral treatments for diseases like brain ...

In a small study, researchers transplanted stem cells into the brains of 12 Parkinson’s patients, stopping progression and ...

Breakthrough research could make any IV drug able to be taken orally for a range of hard-to-treat cancers and other diseases, and redefine how medicines are designed, evaluated and delivered.

Two small clinical trials tested the safety of injecting stem cells into the brains of Parkinson's patients and found no ...

JON HAMILTON, BYLINE: Both studies are preliminary and small but also encouraging ... Some earlier efforts to replace brain ...